Reed E Pyeritz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3970030/publications.pdf

Version: 2024-02-01

104 papers 14,019 citations

76031 42 h-index 94 g-index

106 all docs

106 docs citations

106 times ranked 9731 citing authors

#	Article	IF	CITATIONS
1	Aortopathies and arteriopathies., 2022,, 707-712.		O
2	Cardiovascular Outcomes in Aortopathy. Journal of the American College of Cardiology, 2022, 79, 2069-2081.	1.2	12
3	Clinical Features and Outcomes of Pregnancy-Related Acute Aortic Dissection. JAMA Cardiology, 2021, 6, 58-66.	3.0	29
4	Uncertainty in Genomics Impacts Precision Medicine. Trends in Genetics, 2021, 37, 711-716.	2.9	3
5	Arachnodactyly represented in art. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 163-167.	0.7	1
6	Marfan Syndrome. Journal of the American College of Cardiology, 2021, 77, 3013-3015.	1.2	2
7	Expanding the phenotypic spectrum of Mendelian connective tissue disorders to include prominent kidney phenotypes. American Journal of Medical Genetics, Part A, 2021, 185, 3762-3769.	0.7	O
8	Marfan syndrome. Nature Reviews Disease Primers, 2021, 7, 64.	18.1	99
9	Digital vascular lesions detected by transillumination. American Journal of Medical Genetics, Part A, 2021, , .	0.7	O
10	Cerebrovascular Malformations in a Pediatric Hereditary Hemorrhagic Telangiectasia Cohort. Pediatric Neurology, 2020, 110, 49-54.	1.0	8
11	Persistence of Pulmonary Arteriovenous Malformation after Embolization: Another Reason to Quit Smoking. Radiology, 2019, 292, 771-772.	3.6	O
12	Lack of Growth of Small (â‰ 2 mm Feeding Artery) Untreated Pulmonary Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia. Journal of Vascular and Interventional Radiology, 2019, 30, 1259-1264.	0.2	4
13	Features of Marfan syndrome not listed in the Ghent nosology – the dark side of the disease. Expert Review of Cardiovascular Therapy, 2019, 17, 883-915.	0.6	46
14	Patient re-contact after revision of genomic test results: points to considerâ€"a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2019, 21, 769-771.	1.1	91
15	Marfan syndrome: improved clinical history results in expanded natural history. Genetics in Medicine, 2019, 21, 1683-1690.	1.1	65
16	Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. Journal of Pediatrics, 2019, 204, 250-255.e1.	0.9	26
17	Carnival: A Graph-Based Data Integration and Query Tool to Support Patient Cohort Generation for Clinical Research. Studies in Health Technology and Informatics, 2019, 264, 35-39.	0.2	2
18	Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations. Genetics in Medicine, 2018, 20, 1206-1215.	1.1	50

#	Article	IF	CITATIONS
19	Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. American Journal of Cardiology, 2018, 121, 1094-1101.	0.7	30
20	Fragile X Associated Primary Ovarian Insufficiency (FXPOI): Case Report and Literature Review. Frontiers in Genetics, 2018, 9, 529.	1.1	26
21	Genome sequencing reveals a deep intronic splicing <i>ACVRL1</i> hi> mutation hotspot in Hereditary Haemorrhagic Telangiectasia. Journal of Medical Genetics, 2018, 55, 824-830.	1.5	13
22	Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome. Pediatric Cardiology, 2018, 39, 1453-1461.	0.6	14
23	Covered Stents in the Treatment of Pulmonary Arteriovenous Malformations. Journal of Vascular and Interventional Radiology, 2018, 29, 981-985.	0.2	2
24	Comparison of Outcomes in DeBakey Type Al Versus All Aortic Dissection. American Journal of Cardiology, 2018, 122, 689-695.	0.7	16
25	Familial Vasculopathies: Implications for Exercise and Athletic Competition., 2018,, 171-191.		0
26	Chronobiology of Acute Aortic Dissection in the Marfan Syndrome (from the National Registry of) Tj ETQq0 0 0 rg	BT /Overlo 0.7	ock 10 Tf 50 19
27	A Survey of Pulmonary Arteriovenous Malformation Screening, Management, and Follow-Up in Hereditary Hemorrhagic Telangiectasia Centers of Excellence. CardioVascular and Interventional Radiology, 2017, 40, 1003-1009.	0.9	20
28	Associations of Age and Sex With Marfan Phenotype. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	57
29	Aortic Dilatation Associated With Bicuspid Aortic Valve: Relation to Sex, Hemodynamics, and Valve Morphology (the National Heart Lung and Blood Institute-Sponsored National Registry of Genetically) Tj ETQq1 1 Cardiology, 2017, 120, 1171-1175.	0,7,84314	rgBT /Over
30	Chronobiology of Acute Aortic Syndromes. Heart Failure Clinics, 2017, 13, 697-701.	1.0	6
31	Etiology and pathogenesis of the Marfan syndrome: current understanding. Annals of Cardiothoracic Surgery, 2017, 6, 595-598.	0.6	17
32	Marfan Syndrome â~†. , 2017, , .		0
33	The role of the multidisciplinary health care team in the management of patients with Marfan syndrome. Journal of Multidisciplinary Healthcare, 2016, Volume 9, 587-614.	1.1	51
34	Aortic Complications Associated With Pregnancy in Marfan Syndrome: The NHLBI National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC). Journal of the American Heart Association, 2016, 5, .	1.6	71
35	Shock complicating type A acute aortic dissection: Clinical correlates, management, and outcomes. American Heart Journal, 2016, 176, 93-99.	1.2	25
36	Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia. JAMA - Journal of the American Medical Association, 2016, 316, 943.	3.8	74

#	Article	IF	Citations
37	Aortic Dissection in Patients With Genetically Mediated Aneurysms. Journal of the American College of Cardiology, 2016, 67, 2744-2754.	1.2	84
38	Recent progress in understanding the natural and clinical histories of the Marfan syndrome. Trends in Cardiovascular Medicine, 2016, 26, 423-428.	2.3	50
39	The Expanding Clinical Spectrum of Extracardiovascular and Cardiovascular Manifestations of Heritable Thoracic Aortic Aneurysm and Dissection. Canadian Journal of Cardiology, 2016, 32, 86-99.	0.8	61
40	The IGNITE network: a model for genomic medicine implementation and research. BMC Medical Genomics, 2015, 9, 1.	0.7	189
41	The translational potential of research on the ethical, legal, and social implications of genomics. Genetics in Medicine, 2015, 17, 12-20.	1.1	24
42	Loeys–Dietz syndrome is a specific phenotype and not a concomitant of any mutation in a gene involved in TGF-β signaling. Genetics in Medicine, 2014, 16, 641-642.	1.1	18
43	Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome. New England Journal of Medicine, 2014, 371, 2061-2071.	13.9	457
44	Heritable thoracic aortic disorders. Current Opinion in Cardiology, 2014, 29, 97-102.	0.8	68
45	Pulse Pressure and Type A Acute Aortic Dissection In-Hospital Outcomes (from the International) Tj ETQq1 1 0.78	34314 rgB	T /Overlock
46	"Use it or lose it―as an alternative approach to protect genetic privacy in personalized medicine. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 198-201.	0.8	12
47	What Is the Optimal Medical Therapy for Marfan Syndrome?. Journal of Pediatrics, 2014, 165, 889-890.	0.9	2
48	Cocaine-related Aortic Dissection: Lessons from the International Registry of Acute Aortic Dissection. American Journal of Medicine, 2014, 127, 878-885.	0.6	61
49	Marfan Syndrome and Related Disorders. , 2013, , 1-52.		1
50	Community pharmacists†attitudes towards clinical utility and ethical implications of pharmacogenetic testing. Personalized Medicine, 2013, 10, 793-800.	0.8	65
51	Painless Type B Aortic Dissection: Insights From the International Registry of Acute Aortic Dissection. Aorta, 2013, 1, 96-101.	0.1	10
52	Evaluation of the adolescent or adult with some features of Marfan syndrome. Genetics in Medicine, 2012, 14, 171-177.	1.1	20
53	Incorporating direct-to-consumer genomic information into patient care: attitudes and experiences of primary care physicians. Personalized Medicine, 2012, 9, 683-692.	0.8	39
54	The family history: the first genetic test, and still useful after all those years?. Genetics in Medicine, 2012, 14, 3-9.	1,1	61

#	Article	IF	CITATIONS
55	Long-term implications of emergency versus elective proximal aortic surgery in patients with Marfan syndrome in the Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions Consortium Registry. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 282-286.	0.4	45
56	The 8th international research symposium on the Marfan Syndrome and related conditions. American Journal of Medical Genetics, Part A, 2012, 158A, 42-49.	0.7	21
57	Travels with Victor: Marfan Syndrome and Its Cousins. , 2012, , 67-83.		1
58	The Coming Explosion in Genetic Testing â€" Is There a Duty to Recontact?. New England Journal of Medicine, 2011, 365, 1367-1369.	13.9	79
59	Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis. Genetics in Medicine, 2011, 13, 607-616.	1.1	315
60	The revised Ghent nosology for the Marfan syndrome. Journal of Medical Genetics, 2010, 47, 476-485.	1.5	1,677
61	Transillumination of the fingers for vascular anomalies: a novel method for evaluating hereditary hemorrhagic telangiectasia. Genetics in Medicine, 2009, 11, 356-358.	1.1	3
62	Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease. American Journal of Human Genetics, 2009, 84, 617-627.	2.6	466
63	Surgical Treatment of Patients Enrolled in the National Registry of Genetically Triggered Thoracic Aortic Conditions. Annals of Thoracic Surgery, 2009, 88, 781-788.	0.7	23
64	Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management. Genetics in Medicine, 2008, 10, 469-494.	1,1	130
65	Marfan Syndrome and Related Disorders. Annals of Thoracic Surgery, 2008, 86, 335-336.	0.7	14
66	Medical Management of Marfan Syndrome. Circulation, 2008, 117, 2802-2813.	1.6	260
67	Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart, 2008, 95, 173-175.	1,2	7 3
68	Abdominal visceral findings in patients with Marfan syndrome. Genetics in Medicine, 2007, 9, 208-212.	1,1	32
69	Rationale and design of a randomized clinical trial of \hat{I}^2 -blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. American Heart Journal, 2007, 154, 624-631.	1,2	217
70	Aneurysm Syndromes Caused by Mutations in the TGF-Î ² Receptor. New England Journal of Medicine, 2006, 355, 788-798.	13.9	1,490
71	Characterization of the symptoms associated with dural ectasia in the Marfan patient. American Journal of Medical Genetics, Part A, 2005, 134A, 58-65.	0.7	81
72	What Genes Can't Do. Lenny Moss. Cambridge, MA: The MIT Press, 2003, 228 pp., \$34.95, hardcover. ISBN 0-262-13411-X Clinical Chemistry, 2004, 50, 1109-1110.	1.5	0

#	Article	IF	Citations
73	Genetic counseling for congenital heart disease: New approaches for a new decade. Current Cardiology Reports, 2002, 4, 68-75.	1.3	27
74	Empowering primary care health professionals in medical genetics: How soon? How fast? How far?. American Journal of Medical Genetics Part A, 2001, 106, 223-232.	2.4	136
75	The Marfan Syndrome. Annual Review of Medicine, 2000, 51, 481-510.	5.0	412
76	Replacement of the Aortic Root in Patients with Marfan's Syndrome. New England Journal of Medicine, 1999, 340, 1307-1313.	13.9	599
77	Comparison of heteroduplex analysis, direct sequencing, and enzyme mismatch cleavage for detecting mutations in a large gene,FBN1., 1999, 14, 440-446.		26
78	Impact of Laboratory Molecular Diagnosis on Contemporary Diagnostic Criteria for Genetically Transmitted Cardiovascular Diseases: Hypertrophic Cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome. Circulation, 1998, 98, 1460-1471.	1.6	128
79	Revised diagnostic criteria for the Marfan syndrome. , 1996, 62, 417-426.		1,335
80	A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. American Journal of Obstetrics and Gynecology, 1995, 173, 1599-1606.	0.7	356
81	Mitral valve operation in patients with the Marfan syndrome. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 724-731.	0.4	43
82	Progression of Aortic Dilatation and the Benefit of Long-Term \hat{l}^2 -Adrenergic Blockade in Marfan's Syndrome. New England Journal of Medicine, 1994, 330, 1335-1341.	13.9	1,015
83	A revolution in medicine like no other. FASEB Journal, 1992, 6, 2761-2766.	0.2	7
84	Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cysteine residues in EGF-like domains. Human Mutation, 1992, 1, 366-374.	1.1	131
85	Assessment of genetic risk in congenital heart disease. Journal of the American College of Cardiology, 1991, 18, 338-340.	1.2	17
86	Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature, 1991, 352, 337-339.	13.7	1,901
87	Angular homeostasis VIII. Pursuit of a slowly moving target in a plane: Relevance to lateralization in cardiovascular ontogeny. American Journal of Medical Genetics Part A, 1991, 41, 362-370.	2.4	4
88	First international symposium on the Marfan syndrome. American Journal of Medical Genetics Part A, 1989, 32, 233-238.	2.4	9
89	Conference Report: March of Dimes clinical genetics conference 1988. American Journal of Medical Genetics Part A, 1989, 34, 9-11.	2.4	1
90	Genetics and congenital heart disease: Perspectives and prospects. Journal of the American College of Cardiology, 1989, 13, 1458-1468.	1.2	23

#	ARTICLE	IF	CITATION
91	Marfan Syndrome: Exclusion of genetic linkage to three major collagen genes. American Journal of Medical Genetics Part A, 1988, 29, 457-462.	2.4	30
92	Achondropiasia is not caused by mutation in the gene for type II collagen. American Journal of Medical Genetics Part A, 1988, 29, 955-961.	2.4	16
93	Pulmonary Function in the Marfan Syndrome. Chest, 1987, 91, 408-412.	0.4	70
94	Thoracolumbosacral laminectomy in achondroplasia: Long-term results in 22 patients. American Journal of Medical Genetics Part A, 1987, 28, 433-444.	2.4	51
95	The bingo model of survivorship V. The problems of conformation to the empirical evidence. American Journal of Medical Genetics Part A, 1987, 28, 703-717.	2.4	5
96	Homeostasis VII. A conspectus. American Journal of Medical Genetics Part A, 1986, 24, 735-751.	2.4	11
97	Pulmonary hypertension and interstitial fibrosis in von recklinghausen neurofibromatosis. American Journal of Medical Genetics Part A, 1986, 25, 531-535.	2.4	25
98	Osteogenesis imperfecta with unusual skeletal lesions: Report of three families. American Journal of Medical Genetics Part A, 1985, 21, 257-269.	2.4	39
99	Enzyme therapy: Treatment of inborn errors of metabolism by transplantation. Nature, 1984, 312, 405-406.	13.7	9
100	Pseudoxanthoma elasticum: High calcium intake in early life correlates with severity. American Journal of Medical Genetics Part A, 1984, 19, 235-244.	2.4	63
101	Ehlers-Danlos syndrome IV due to a novel defect in type III procollagen. American Journal of Medical Genetics Part A, 1984, 19, 607-622.	2.4	33
102	Pneumothorax in the Marfan Syndrome: Prevalence and Therapy. Annals of Thoracic Surgery, 1984, 37, 500-504.	0.7	130
103	Maternal and fetal complications of pregnancy in the Marfan syndrome. American Journal of Medicine, 1981, 71, 784-790.	0.6	242
104	Plasma exchange removes glycosphingolipid in Fabry disease. American Journal of Medical Genetics Part A. 1980. 7. 301-307.	2.4	11